Anti-human CD19-CD22 T cell therapy |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CLIC-1901 (Ottawa Hospital Research Institute) |
CLIC-1901 |
Phase 2 Clinical |
Ottawa Hospital Research Institute |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
UCART-19 |
S-68587; UCART-19 |
Phase 1 Clinical |
Cellectis |
Leukemia, Lymphoid; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.) |
|
Phase 1 Clinical |
Hebei Yanda Hospital, China Immunotech Co Ltd |
Lymphoma, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Bioceltech) |
|
Clinical |
Bioceltech Therapeutics |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19 CAR-T cell therapy (National University of Malaysia) |
|
Phase 3 Clinical |
National University Of Malaysia |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) |
|
Phase 1 Clinical |
Chongqing Xinqiao Hospital |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
4G7SDIE |
|
Clinical |
Synimmune, The University Of Tubingen |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
TI-1007 |
TI-1007 |
Phase 2 Clinical |
Timmune Biotech |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
MC-19PD1 CAR-T cell therapy (Peking University) |
|
Phase 1 Clinical |
Peking University |
Lymphoma, B-Cell |
Details
|
CD19 CARvac T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) |
|
Phase 2 Clinical |
Wuhan Sian Medical Technology, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) |
|
Clinical |
Leidos |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
GNC-038 |
GNC-038 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
Ut Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
PCAR-019 (Anke Biotechnology) |
|
Phase 1 Clinical |
Anhui Anke Biotechnology (Group)Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) |
|
Phase 1 Clinical |
Immune Cell |
Lymphoma, B-Cell; Leukemia, Lymphoid; Leukemia, B-Cell |
Details
|
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) |
|
Phase 1 Clinical |
China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital |
Lymphoma, B-Cell |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase 2 Clinical |
The University Of Texas M.D. Anderson Cancer Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Nanchang University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19 CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Lymphoma, B-Cell; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
PBCAR-0191 |
PBCAR-0191 |
Phase 2 Clinical |
Baxalta |
Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin |
Details
|
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
XYF19 CAR-T cell therapy (Xijing Hospital) |
|
Phase 1 Clinical |
Xijing Hospital |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology |
Leukemia, Lymphoid |
Details
|
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase 1 Clinical |
Icar Bio, China |
Leukemia; Lymphoma |
Details
|
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
BZ019 |
BZ-019 |
Phase 1 Clinical |
Shanghai Cell Therapy Research Institute |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular |
Details
|
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 2 Clinical |
Wuhan Bio-Raid Biotechnology |
Hematologic Diseases; Lymphoma, B-Cell |
Details
|
CD19-CAR |
CD19-CAR |
Phase 1 Clinical |
The University Of Texas M.D. Anderson Cancer Center |
Leukemia; Lymphoma |
Details
|
CTA-101 |
CTA-101 |
Phase 1 Clinical |
Nanjing Bioheng Biotech, Xuzhou Medical University (Xzmu), Nanjing Medical University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
YTB-323 |
YTB-323 |
Phase 1 Clinical |
Novartis Pharma Ag |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
ET-019002 |
ET-019002 |
Phase 1 Clinical |
Eureka Therapeutics |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) |
|
Phase 1 Clinical |
Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Sinobioway) |
|
Phase 2 Clinical |
Sinobioway Biomedicine Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma |
Details
|
Obexelimab |
AMG-729; XmAb-5871 |
Phase 3 Clinical |
Xencor |
Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic |
Details
|
aCD19z |
aCD19z |
Phase 1 Clinical |
Christie Hospital Nhs Foundation Trust |
Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 CAR T-cell therapy (Fujian Medical University) |
|
Phase 3 Clinical |
Fujian Medical University |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Uppsala University) |
|
Phase 2 Clinical |
Uppsala University |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
PTG-01 |
PTG-01 |
Phase 1 Clinical |
Protheragen |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) |
WZTL002-1 |
Phase 1 Clinical |
The Malaghan Institute Of Medical Research |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology) |
|
Phase 1 Clinical |
Genxi Biotechnology (Shanghai) Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
MB-CART2019.1 |
MB-CART2019.1 |
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
TG-1801 |
NI-1701; TG-1801 |
Phase 1 Clinical |
Novimmune |
Lymphoma, B-Cell |
Details
|
GTB-1550 |
DT-2219; OXS-1550; DT-2219ARL; IND-100780 |
Phase 2 Clinical |
University Of Minnesota |
Leukemia; Lymphoma, B-Cell |
Details
|
4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Neoplasms |
Details
|
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) |
|
Phase 1 Clinical |
First Affiliated Hospital Of Zhejiang University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
GNR-084 |
GNR-084 |
Phase 2 Clinical |
Generium Pharmaceuticals, Iontas |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
AUTO-1 |
AUTO1; AUTO-1 |
Phase 2 Clinical |
University College London |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore) |
|
Phase 1 Clinical |
National University Health System |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) |
SENL-B19 |
Phase 2 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Leukemia; Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma |
Details
|
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) |
CARCIK-CD19; CIK-CAR.CD19 |
Phase 2 Clinical |
Fondazione Matilde Tettamanti Menotti De Marchi Onlus |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Coltuximab ravtansine |
SAR-3419; huB4-DM4 |
Phase 2 Clinical |
Immunogen |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) |
BPX-401 |
Phase 2 Clinical |
Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu |
Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma |
Details
|
PCAR-119 (PersonGen Biomedicine) |
PCAR-119 |
Phase 2 Clinical |
|
Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Prolymphocytic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) |
yinnuokati-19 |
Phase 2 Clinical |
Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Multiple Myeloma |
Details
|
GC-007F (Gracell Biotechnology) |
GC-007F |
Phase 1 Clinical |
Genxi Biotechnology (Shanghai) Co Ltd |
Lymphoma, B-Cell |
Details
|
AFM-11 |
AFM-11 |
Phase 1 Clinical |
Affimed |
Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) |
|
Phase 1 Clinical |
Timmune Biotech |
Leukemia; Lymphoma, Non-Hodgkin |
Details
|
CD19 chimeric antigen receptor T cell therapy (Takara Bio) |
TBI-1501 |
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center, Takara Bio |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) |
|
Phase 1 Clinical |
Hebei Yanda Hospital |
Lymphoma, B-Cell |
Details
|
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases, University Of Pittsburgh |
Immunologic Deficiency Syndromes |
Details
|
HuCART19 |
|
Phase 2 Clinical |
National Cancer Institute, Kite Pharma |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
|
Phase 1 Clinical |
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Multiple Myeloma; Lymphoma |
Details
|
PBLTT52CAR19 |
|
Phase 1 Clinical |
Great Ormond Street Hospital For Children Nhs Foundation Trust |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Lymphoma, B-Cell; Leukemia; Leukemia, B-Cell |
Details
|
CTL-119 |
CTL-119 |
Phase 2 Clinical |
University Of Pennsylvania, Novartis Pharma Ag |
Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
IM19CAR-T |
|
Phase 2 Clinical |
Beijing Yimiao Medical Technology Co Ltd |
Leukemia; Hematologic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
Humanized CD19 CAR-T cell therapy (Yake) |
YK-C19 |
Phase 1 Clinical |
Yake Biotechnology |
Lymphoma, B-Cell; Leukemia, Lymphoid |
Details
|
Murine CD19 CAR-T cell therapy (Yake) |
|
Phase 1 Clinical |
Yake Biotechnology |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology) |
|
Phase 1 Clinical |
Wuhan Sian Medical Technology |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Virus-specific-CD19.CAR |
|
Phase 1 Clinical |
Baylor College Of Medicine |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
H-31970-SAGAN |
H-31970-SAGAN |
Phase 1 Clinical |
Baylor College Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
Phase 1 Clinical |
Fujian Medical University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) |
|
Phase 3 Clinical |
Chaim Sheba Medical Center At Tel Hashomer |
Leukemia, Myeloid, Acute |
Details
|
Anti-CD19 CAR T-cell therapy (University College London) |
4G7-CARD |
Phase 1 Clinical |
University College London |
Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-19 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell |
Details
|
ET190L1-ARTEMIS T cells (Eureka Therapeutics) |
ET190; ET-190; ET190L1; ET190L1-ARTEMI |
Phase 1 Clinical |
Eureka Therapeutics |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
AUTO-3 |
AUTO-3 |
Phase 2 Clinical |
University College London |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
TAK-007 |
TAK-007 |
Phase 2 Clinical |
University Of Texas M. D. Anderson Cancer Center |
Lymphoma, B-Cell |
Details
|
RO-7227166 |
RO-7227166 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Lymphoma, Non-Hodgkin |
Details
|
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) |
|
Phase 2 Clinical |
Xuanwu Hospital Of Capital Medical University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Leukemia; Lymphoma, B-Cell |
Details
|
Duvortuxizumab |
MGD-011; JNJ-64052781 |
Phase 1 Clinical |
Macrogenics |
Hematologic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) |
|
Phase 2 Clinical |
Shanghai Genechem Co Ltd |
Lupus Erythematosus, Systemic; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, Non-Hodgkin |
Details
|
CART-19 cells (Henan Hualong Biotechnology) |
|
Phase 2 Clinical |
Henan Hualong Biotechnology |
Leukemia, Lymphoid |
Details
|
Anti-CD19 CAR T-cell therapy (Shanghai Children's Medical Center) |
|
Phase 2 Clinical |
Shanghai Children'S Medical Center, Miltenyi Biotec |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) |
|
Phase 1 Clinical |
Juno Therapeutics |
Hematologic Neoplasms |
Details
|
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti CD19 chimeric antigen receptor T cell therapy (Beijing Boren Hospital) |
|
Phase 2 Clinical |
Beijing Boren Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) |
|
Phase 1 Clinical |
Nagoya University, Shinshu University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 2 Clinical |
Suzhou University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells |
TAK-940 |
Phase 1 Clinical |
Takeda |
Neoplasms |
Details
|
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 1 Clinical |
Shanghai Longyao Biotechnology |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) |
|
Phase 2 Clinical |
Bioray Laboraytories Inc |
Leukemia |
Details
|
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) |
|
Clinical |
Nanjing Cart Medical Technology |
Neoplasms |
Details
|
CAR-CD19 T cell therapy |
|
Phase 2 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
CD19.CAR-VST |
CD19.CAR-VST |
Phase 1 Clinical |
Baylor College Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Uclas Jonsson Comprehensive Cancer Center |
Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 1 Clinical |
Kecellitics Biotech Company Ltd |
Leukemia; Lymphoma |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) |
|
Clinical |
Hebei Senlang Biological Technology Co Ltd |
Leukemia |
Details
|
Senl-1904A |
Senl-1904A; Senl_1904A |
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
TAC01-CD19 |
TAC01-CD19 |
Phase 2 Clinical |
Triumvira Immunologics |
Lymphoma, B-Cell |
Details
|
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) |
XLCART-001 |
Phase 2 Clinical |
Nanjing Medical University |
Lymphoma, B-Cell |
Details
|
ICT19G1 |
ICT-19G1 |
Phase 1 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University |
Lymphoma, B-Cell |
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 1 Clinical |
The First Affiliated Hospital Of Nanchang University |
Multiple Myeloma |
Details
|
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase 1 Clinical |
Henan Provincial Cancer Hospital |
Lymphoma, B-Cell |
Details
|
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Neoplasms |
Details
|
CLBR-001/SWI-019 |
CLBR-001/SWI-019 |
Phase 1 Clinical |
California Institute For Biomedical Research, Abbvie Inc |
Lymphoma, B-Cell |
Details
|
GC-012F |
GC-012F |
Phase 1 Clinical |
Genxi Biotechnology (Shanghai) Co Ltd |
Multiple Myeloma |
Details
|
CAR-T 19 cell therapy (University of Pennsylvania) |
|
Phase 2 Clinical |
University Of Pennsylvania |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19.CAR T Cells (University Hospital Heidelberg) |
|
Phase 2 Clinical |
University Of Heidelberg |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
U-CART (Shanghai Bioray Laboratory Inc) |
|
Phase 2 Clinical |
Bioray Laboraytories Inc |
Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) |
PZ-01 |
Clinical |
Pinze Lifetechnology |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy |
GC-197 |
Phase 2 Clinical |
Genxi Biotechnology (Shanghai) Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) |
|
Phase 1 Clinical |
Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd |
Lymphoma, B-Cell |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) |
|
Phase 2 Clinical |
University Of Alberta |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) |
|
Phase 1 Clinical |
Kunming Medical University |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19-CART |
|
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) |
|
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd, Kunming Medical University, Zhejiang University |
Leukemia; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) |
LCAR-L10D |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) |
|
Phase 2 Clinical |
Shanghai Zhongshan Hospital, Hrain Biotechnology |
Candidiasis, Vulvovaginal; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CTA-30X |
CTA-30X; CTA30X |
|
|
|
Details
|
GC007g |
GC-007G |
Phase 1 Clinical |
Genxi Biotechnology (Shanghai) Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
CC-97540 |
CC-97540 |
Phase 1 Clinical |
Juno Therapeutics |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 CAR-T Cell Therapy (PersonGen) |
|
|
|
|
Details
|
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
|
Phase 1 Clinical |
China Immunotech Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
JCAR-014 |
JCAR-014 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) |
|
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital |
Leukemia |
Details
|
3rd-gen-CD19-CAR |
3rd-gen-CD19-CAR |
Phase 2 Clinical |
Bluebird Bio |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
JCAR-015 |
JCAR-15; JCAR-015; 19-28z-T-Cells; 19-28z+ T cells; 19-28z CAR T cells |
Phase 2 Clinical |
Seattle Children'S Research Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, Juno Therapeutics |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Lymphoma, B-Cell |
Details
|
BinD-19 (Shenzhen BinDeBio) |
BinD-19 |
Phase 2 Clinical |
Shenzhen Bindebio Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
ALLO-501 |
ALLO-501 |
Phase 1 Clinical |
Cellectis |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
TC-110 |
TC-110 |
Phase 2 Clinical |
Tcr2 Therapeutics |
Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19 CAR-T (HuaDao CAR-Tcell) |
|
Phase 1 Clinical |
Huadao (Shanghai) Biopharma Co Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
AMG-562 |
AMG-562 |
Phase 1 Clinical |
Amgen Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Juventas) |
CNCT19; CNCT-19; HY001 |
Phase 2 Clinical |
Heyuan Biotechnology (Tianjin) Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) |
|
Phase 1 Clinical |
University Hospitals Cleveland Medical Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) |
|
Phase 1 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
CD19 CAR-T cell (Pregene) |
|
Phase 2 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
K193 bispecific antibody |
K-193 |
Phase 1 Clinical |
Beijing Lvzhu Biological Technology Co Ltd |
Lymphoma, B-Cell |
Details
|
pCAR-19B |
|
Phase 1 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
A-319 |
A-319 |
Phase 1 Clinical |
Generon Corp |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|